Table 1.
Patient characteristics in selected studies of stereotactic body radiotherapy (SBRT) for hepatocellular carcinoma (HCC).
| Authors (Year) | Study Type | No. of Patients (Lesions) |
Age (Years) * | BCLC Stage | Tumor Size (mm) * | Child–Pugh Class | Prior Tx |
|---|---|---|---|---|---|---|---|
| Kimura et al. (2021) [11] | Phase II | 36 (36) | 73.5 (57–85) | 0: 12 A: 16 C: 8 |
23 (10–50) | A: 33 B7: 2 B8: 1 |
0% |
| Yoon et al. (2020) [12] | Phase II | 50 (53) | 64 (41–74) | NA | 13 (7–31) | A: 50 | 96% |
| Durand–Labrunie et al. (2020) [13] | Phase II | 43 (43) | 72 (43–91) | NA | 28 (10–60) | A: 37 B7: 3 B8-9: 2 |
0% |
| Jang et al. (2020) [14] | Phase II | 65 (73) | 61 (44–84) | 0: 25 A: 32 B: 4, C: 4 |
24 (10–99) | A: 64 B7: 1 |
100% |
| Park et al. (2020) [15] | Phase II | 290 (319) | 61 (36–90) | NA | 17 (7–60) | A: 250 B: 40 |
97% |
| Kim et al. (2019) [16] | Phase I/II | 32 (35) | 59.5 (42–83) | A: 31 C: 1 |
21 (10–45) | A: 32 | 16% |
| Takeda et al. (2016) [17] | Phase II | 90 (90) | 73 (48–85) | 0: 31 A: 45 C: 16 |
23 (10–40) | A: 82 B7: 7 B8: 1 |
64% |
| Lasley et al. (2015) [18] | Phase I/II | 59 (65) | 61 (24–86) | NA | NA | A: 38 B7: 17 B8+: 4 |
15% |
| Bujold et al. (2013) [19] | Phase I/II | 102 | 69 (40–90) | A/B: 35 C: 67 |
72 (14–231) | A: 102 | 52% |
| Kang et al. (2012) [20] | Phase II | 47 (55) | NA | A: 8 B: 31 C: 8 |
29 | A: 41 B7: 6 |
57% |
Abbreviations: BCLC = Barcelona Clinic Liver Cancer, Tx = treatment, NA = not available. * The values represent the median (range).